QURE$30.12
$29.84
Chart
Performance
Key Stats
AI QURE Summary
Powered by LiveAIAI Scoreboard
Powered by LiveAIOverall Analysis
NeutraluniQure N.V. operates in a high-potential gene therapy market with promising clinical candidates. However, the company is currently unprofitable and facing significant cash burn. Technical indicators suggest a neutral short-term outlook, while fundamental analysis highlights the need for continued progress in clinical trials and improved financial performance.
Thematic
uniQure is positioned in the rapidly growing gene therapy sector, addressing rare and devastating diseases. Advancements in genetic medicine and increasing investor interest in biotech provide strong thematic tailwinds.
Fundamental
uniQure is a development-stage biotechnology company with significant cash burn and no reported profits. While revenue is increasing, it remains low. The company has a substantial amount of debt relative to its current assets, but also sufficient cash equivalents. The negative EPS and P/S ratios highlight its pre-revenue/pre-profitability stage.
Technical
The stock is trading within a medium-term range, exhibiting mixed signals across different timeframes. While longer-term moving averages suggest a potential for upward movement, shorter-term indicators show increased volatility and a neutral to slightly bearish sentiment.
| Factor | Score |
|---|---|
| Gene Therapy Market Growth | 90 |
| Rare Disease Focus | 95 |
| Pipeline Development | 80 |
| Biotechnology Innovation | 85 |
| Regulatory Landscape | 60 |
| Factor | Score |
|---|---|
| Valuation | 10 |
| Profitability | 0 |
| Growth | 30 |
| Balance Sheet Health | 40 |
| Cash Flow | 15 |
| Factor | Score |
|---|---|
| Trend Analysis | 50 |
| Momentum | 60 |
| Volume Confirmation | 40 |
| Support & Resistance | 55 |
| Short-Term Oscillators | 50 |
AI Investing Checklist
Powered by LiveAIBullish Points (9)
Positive Short-Term Performance
The stock has shown positive performance over the last 5 days (+4.55%) and 1 month (+6.54%).
Strong Long-Term Performance
The stock has achieved a significant 1-year return of +81.88%.
Bearish Points (13)
Negative P/E Ratio
The trailing P/E ratio is null or negative (-5.1 TTM, -4.0 for 2024, -2.7 for 2023), indicating the company is not currently profitable on a per-share basis.
High Price-to-Sales Ratio
The Price-to-Sales (P/S) ratio is high (91.5 TTM, 35.7 for 2024, 52.4 for 2023), suggesting the stock is expensive relative to its revenue.
Calendar
July 2025
29
Next Earnings Date
H: $-0.59
A: $-0.76
L: $-0.91
H: 8.54M
A: 4.96M
0Profile
uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases in the United States. The company offers HEMGENIX that allows people living with hemophilia B to produce factor IX, which can lower the risk of bleeding. Its lead product candidate is AMT-130, a gene therapy candidate, which is in Phase I/II clinical study for the treatment of Huntington's disease. The company also develops AMT-260, which is in Phase I/IIa clinical trial for the treatment of mesial temporal lobe epilepsy; AMT-162, which is in Phase I/IIa clinical trial to treat superoxide dismutase enzyme-amyotrophic lateral sclerosis; and AMT-191, an investigational gene therapy candidate which is in phase I/IIa clinical trial for the treatment of fabry disease. It has a licensing agreement with Apic Bio to develop, manufacture, and commercialize intrathecally administered investigational gene therapy for ALS caused by mutations in SOD-1; and development and commercial supply agreement with CLS Bhering. uniQure N.V. was founded in 1998 and is headquartered in Amsterdam, the Netherlands.
Seasonals
Price Target
35.89 USD
The 39 analysts offering 1 year price forecasts for QURE have a max estimate of 70.30 and a min estimate of 13.55.
Debt Level and Coverage
Financial Position Analysis
Ownership
Capital Structure
Valuation - Summary
Valuation - Ratios
Revenue to Profit Conversion
Balance Sheet
Income Statement
Cash Flow
Related Companies
Powered by LiveAIWeight: 95
Direct gene therapy competitor focusing on severe genetic diseases, including those targeting blood disorders, with FDA-approved products.
Weight: 90
Leading gene therapy company focused on rare neuromuscular diseases, especially Duchenne Muscular Dystrophy, with multiple approved gene therapies.
Weight: 90
Major pharmaceutical company with a significant gene therapy presence (e.g., Zolgensma for SMA) and a robust pipeline in genetic medicines.
Weight: 88
Pioneer in gene editing (CRISPR/Cas9), often seen as complementary or competitive to AAV gene therapy for various genetic diseases, with an approved product.